Brain degeneration

Brain degeneration" is not the name of a specific molecule or receptor. Instead, it is a broad pathological term used to describe the progressive loss of structure or function of neurons in the brain, commonly associated with neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease[1][2]. The term does not refer to any single therapeutic target but rather encompasses multiple underlying molecular mechanisms and pathways that contribute to neuronal death and dysfunction. Research into neurodegeneration focuses on identifying specific molecules—such as kinases (e.g., MAPK1), receptors (e.g., glutamate receptors), transcription factors, immune cell subsets (e.g., microglia), and proteins involved in protein aggregation or autophagy—that may serve as drug targets for these conditions[1][2][4]. Therefore, "brain degeneration" itself cannot be classified as a canonical target; instead, it describes an outcome resulting from various molecular events. There is something incorrect with this entry because "brain degeneration" is too broad and non-specific—it does not correspond to an individual molecule or receptor that can be directly targeted by drugs. For structured data purposes, more precise targets should be specified based on the context of interest within neurodegenerative research[1][2].

Other names

Brain degenerationNeurodegeneration (common scientific term)